Kyverna Therapeutics, Inc. (KYTX) Balance Sheet
As of 2026-06-30 (10-Q), Kyverna Therapeutics, Inc. (KYTX) reported total assets of $219.8M, total liabilities of $54.3M and shareholders' equity of $165.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $31.8M. Long-term debt: $24.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KYTXKyverna Therapeutics, Inc.Follow KYTX — free
—
Price chart with a free account
- Market cap
- 333.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 96.6 | 124.1 | 31.8 | |
| Short-term investments | 189.4 | 155.2 | 167.6 | |
| Current assets | 290.6 | 283.0 | 206.5 | |
| Total assets | 304.6 | 293.8 | 219.8 | |
| Current liabilities | 33.8 | 36.5 | 22.8 | |
| Long-term debt | — | 24.7 | 24.9 | |
| Total liabilities | 38.1 | 61.6 | 54.3 | |
| Shareholders' equity | 266.6 | 232.3 | 165.5 |
USD millions · SEC XBRL
Kyverna Therapeutics, Inc. — questions
- How much cash does Kyverna Therapeutics, Inc. have?
- $31.8M in cash and cash equivalents as of 2026-06-30.
- How much debt does Kyverna Therapeutics, Inc. have?
- $24.9M of long-term debt as of 2026-06-30.
- What are Kyverna Therapeutics, Inc.'s total assets?
- $219.8M as of 2026-06-30.
- What is Kyverna Therapeutics, Inc.'s shareholders' equity?
- $165.5M as of 2026-06-30.
Every figure on this page comes from Kyverna Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.